Ligand Pharmaceuticals Incorporated (LGND) fair value analysis
Nasdaq · Updated 2026-10-19
LGND price how computed
Forward Fair Value verdict
OvervaluedLGND is trading at more than a 25% premium to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $295.54
- Sector
- Healthcare
- 12-month range
- $181.65–$322.61
- Market cap
- $5.89B
- From 52-week high
- -8.4%
- Shares outstanding
- 19.9M
- Rank in Healthcare by discount to fair value
- #89 of 108
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that focuses on the development and commercialization of small molecule drugs for various therapeutic areas including oncology, cardiovascular disease, and metabolic disorders. The company operates primarily in the United States with research, development, and commercial operations across multiple locations.
LGND currently ranks #89 of 108 Healthcare stocks by discount to fair value. It has screened as Overvalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $5.89B
- P/E (trailing)
- 33x
- Revenue (TTM)
- $291M
- Net margin
- 67.9%
- EPS (TTM)
- $9.06
- Gross margin
- 95.0%
- Debt / equity
- 1.17
- Revenue growth (3-yr avg)
- 31.3%
- Shares outstanding
- 19.9M
Derived indicators how computed
- Quality grade
- A
- Margin trend
- Expanding
- 52-week position
- The top quarter of its range
Technicals how computed
- RSI (14-day)
- 53 · neutral
- 50-day average
- $292.45
- 200-day average
- $246.94
- Moving-average state
- 50-day above 200-day (golden cross state); price above both averages
Dividends how computed
- Dividend
- None in the last 12 months (last ex-date 2010-07-02)
Earnings how computed
- Next earnings report
- 2026-10-29 (pre-market)
- Last 8 quarters vs consensus
- 7 beat, 1 missed
- Quarter by quarter
- 2026-06 ▲ beat (+65.7%)
2026-03 ▼ miss (-9.4%)
2025-12 ▲ beat (+236.5%)
2025-09 ▲ beat (+60.1%)
2025-06 ▲ beat (+14.3%)
2025-03 ▲ beat (+9.9%)
2024-12 ▲ beat (+6.7%)
2024-09 ▲ beat (+36.3%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 10 buy · 0 hold · 0 sell (10 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $344
- Target vs last price
- +16.4%
What our data shows for LGND
- Our model validated 17 trailing price-to-earnings windows for LGND, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $181.65–$322.61.
- The 14-day relative strength index sits at a neutral 53.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for LGND
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent LGND news
TickrTrends' derived news-sentiment signal for LGND is currently leaning positive, computed from recent coverage.
- Ligand (LGND)-AvenCell Deal: Most of the Funding Is Tied to Milestones (insidermonkey.com, 2026-09-27)
TickrTrends take: Ligand's funding arrangement with AvenCell, where most capital is contingent on achieving milestones, suggests the company is managing cash deployment cautiously rather than committing large upfront investments. This milestone-based structure reduces near-term cash burn but also introduces execution risk that could affect the company's ability to realize the deal's full financial benefit. Given TickrTrends' current assessment that LGND is overvalued, investors focused on valuation metrics should monitor whether Ligand can meet these milestones efficiently and whether the deal ultimately delivers sufficient returns to justify current pricing in the Healthcare sector. - Ligand to Participate in September Investor Conferences (manilatimes.net, 2026-08-26)
TickrTrends take: Ligand Pharmaceuticals' participation in September investor conferences provides an opportunity for management to address investor concerns and discuss the company's pipeline and financial prospects directly with the market. Given TickrTrends' current assessment that LGND is overvalued, investors attending these conferences may scrutinize management's guidance on revenue growth, margin expansion, and return on capital to determine whether the current valuation is justified. For valuation-focused readers, these conferences represent a key moment to evaluate whether management commentary supports the stock's recent pricing or suggests further compression may be warranted.
What people are saying
Follow the LGND conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — # TickrTrends Indicator Summary for LGND LGND's 50/200-day trend state improved this week, transitioning from mixed to uptrend. The stock remains classified as overvalued according to current valuation metrics. The positive momentum shift in trend positioning represents the primary technical development in LGND's derived indicators this week.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is LGND stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), LGND is trading at more than a 25% premium to estimated fair value and screens as overvalued. The exact fair value and discount are available to subscribers.
What is LGND's TickrTrends verdict?
LGND's current verdict is Overvalued, refreshed with every weekly Forward Fair Value run.
How does LGND compare to other Healthcare stocks?
LGND ranks #89 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is LGND overbought or oversold?
LGND's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does LGND pay a dividend?
LGND has paid no dividend in the last twelve months; its last ex-dividend date on file was 2010-07-02.
When does LGND report earnings next?
LGND's next earnings report is scheduled for 2026-10-29 (pre-market), per the published earnings calendar.
Does LGND usually beat earnings estimates?
Over its last 8 reported quarters LGND beat the consensus estimate 7 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about LGND?
Of 10 analysts covering LGND, 10 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $344 (+16.4% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
LGND vs ALKS · LGND vs CDNA · LGND vs CRL · LGND vs GILD · LGND vs HUM